Compare QCLS & KYNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | QCLS | KYNB |
|---|---|---|
| Founded | 2014 | 1993 |
| Country | United States | United States |
| Employees | 2 | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.6M | 31.9M |
| IPO Year | N/A | N/A |
| Metric | QCLS | KYNB |
|---|---|---|
| Price | $3.47 | $6.92 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 503.9K | 26.8K |
| Earning Date | 05-14-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $0.15 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.50 | $6.32 |
| 52 Week High | $8.17 | $9.58 |
| Indicator | QCLS | KYNB |
|---|---|---|
| Relative Strength Index (RSI) | 42.89 | 48.59 |
| Support Level | $3.38 | $6.56 |
| Resistance Level | $3.86 | $7.58 |
| Average True Range (ATR) | 0.31 | 0.37 |
| MACD | -0.02 | 0.06 |
| Stochastic Oscillator | 19.18 | 61.93 |
Q/C Technologies Inc is engaged in building blockchain infrastructure that is faster and more energy-efficient. The company uses laser-based processors inspired by quantum technology that can solve complex problems at the speed of light. By combining photonic computing with cryptocurrency systems, the company creates powerful and sustainable solutions for the next generation of blockchain applications.
Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.